<DOC>
	<DOCNO>NCT00003959</DOCNO>
	<brief_summary>RATIONALE : A vaccine make person 's myelodysplasia cell may make body build immune response kill cancer cell . Combining vaccine therapy sargramostim may kill cancer cell . PURPOSE : Phase I trial study effectiveness vaccine therapy plus sargramostim treating patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether specific T-cell response induce patient myelodysplastic syndrome treat mutant N- , K- , H-ras peptide vaccine ( limited specific N- , K- , H-ras peptide mutation bone marrow ) intradermal sargramostim ( GM-CSF ) . II . Determine whether HLA type ability respond immunologically common recall antigens correlate induction anti-ras immune response patient treat regimen . III . Assess toxicity mutant N- , K- , H-ras peptide vaccine patient . OUTLINE : Patients receive sargramostim ( GM-CSF ) intradermally day 1-10 . Patients receive mutant N- , K- , H-ras peptide vaccine ( limited specific N- , K- , H-ras mutation bone marrow ) intradermally day 7 . Treatment repeat every 4 week 5 course absence disease progression unacceptable toxicity . Patients follow 2 6 week last vaccination . PROJECTED ACCRUAL : A total 25-70 patient accrue study 12-15 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven myelodysplastic syndrome ( MDS ) 1 follow classification : Refractory anemia Refractory anemia ring sideroblast Refractory anemia excess blast Chronic myelomonocytic leukemia History MDS , receive chemotherapy acute leukemia within past 12 month , remission Myelodysplastic disease must stable ( anticipated require chemotherapy least 4 month ) Must 1 follow N , K , Hras peptide mutation : Progenitor cell contain aspartic acid , valine , serine substitution codon 12 , OR Aspartic acid arginine substitution codon 13 PATIENT CHARACTERISTICS : Age : Over 17 Performance status : ECOG 0 1 Life expectancy : Greater 5 month Hematopoietic : WBC least 1,500/mm3 Platelet count least 50,000/mm3 Hepatic : Not specify Renal : Not specify Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Fertile patient must use effective contraception No medical condition might prevent completion study prevent immunological response study regimen No concurrent serious medical illness No active bleeding PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : No concurrent immunosuppressive drug include systemic steroid antiinflammatory drug Radiotherapy : No prior irradiation spleen Surgery : No prior splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>